The authors of a systematic review and meta-analysis have identified significant associations between blood hydroxychloroquine levels and adherence to the drug among patients with systemic lupus erythematosus.
Timing of biologic DMARD use is important in the treatment of children with newly diagnosed polyarticular course juvenile idiopathic arthritis, with early use significantly more effective in reducing disease activity than delayed use, research shows.
First-line etanercept given together with methotrexate does not offer substantial benefits over a methotrexate treat-to-target strategy for patients with very early rheumatoid arthritis, according to findings from the VEDERA study.
The addition of plasma exchange to standard therapy does not reduce the risk for all-cause mortality or end-stage renal disease among patients with severe ANCA-associated vasculitis, suggest findings from the PEXIVAS trial.
Among patients with psoriatic arthritis, higher disease activity is associated with lower cholesterol efflux capacity, a measure of high-density lipoprotein cholesterol quality and quantity, researchers report.
An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.
A 12-week program of arm- and hand-strengthening and stretching exercises significantly improves function, dexterity, performance of daily activities, and quality of life in people with systemic lupus erythematosus, research shows.
Patients with spondyloarthritis are less likely to remain on tumor necrosis factor inhibitor treatment and achieve remission if they disagree with their physicians on the level of their disease activity, researchers report in Rheumatology.
The elevated risk for sarcopenia in rheumatoid arthritis patients is strongly influenced by higher daily glucocorticoid doses as well as older age, lower BMI, and lower body fat mass, research suggests.
Real-world findings suggest that nonresponse to certolizumab pegol based on CDAI scores at 3 months is a good indicator that patients with rheumatoid arthritis are unlikely to achieve the therapeutic target of low disease activity at 1 year.